Systemic Lupus Erythematosus (SLE) Clinical Trial
— RapamuneOfficial title:
Prospective Study of Rapamycin for the Treatment of SLE
Verified date | June 2023 |
Source | State University of New York - Upstate Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. It involves multiple organs including the joints, skin, kidneys and central nervous system. The disease process is caused by a dysfunction of the immune system. The drugs currently used for the treatment of SLE are only partially effective and carry significant risks for side-effects. Patients that were resistant or intolerant to conventional medication have been effectively treated with Rapamycin and were able to decrease the amount of prednisone they needed. The purpose of this study is to prospectively determine the therapeutic efficacy and mechanism of action of Rapamune in patients with SLE. Healthy subjects not receiving Rapamune will be asked to donate blood to serve as controls. As part of the research effort to understand the reason for the variations in the effects of treatment drugs by different individuals, a sub-study of the DNA makeup of subjects enrolled in the trial will also be done. The purpose of the sub-study is to possibly determine whether different responses to the drugs used to treat SLE have a correlation with the differences in the genetic makeup of the subjects.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 16, 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For SLE Subjects: - SLE patients who exhibit ongoing disease activity by SLEDAI greater or equal to 4. - SLE patients whose disease activity is controlled by administration of corticosteroids, most commonly, at least 10 mg/day of prednisone. - 18 years of age or older. - Updated vaccinations prior to study entry. - Use of effective contraception for male patients before, during and up to 12 weeks after sirolimus therapy. For Healthy Control Subjects: - 18 years of age or older - Must be matched with one of the SLE patients enrolled in the study by age, gender and ethnic origin - Must not have any acute or chronic illness. Exclusion Criteria: For SLE Subjects: - Patients who are pregnant. - Patients with allergy or intolerance to sirolimus. - Patients with life-threatening manifestations of SLE. - Patients with proteinuria exceeding 500 mg/24 h or urine protein/creatine ratio >0.5. - Patients with total cholesterol > 300 mg/dl or triglyceride > 400 mg.dl will be excluded. - Patients with acute infection requiring antibiotics. - Patients on sirolimus who develop infections and require intravenous antibiotics and fail to show clinical improvement in 5 days. - Patients concurrently undergoing B cell-depleting therapy, cyclophosphamide, cyclosporine, and tacrolimus. - Patients who have received investigational biologic B-cell depleting products within one year of study initiation. - Patients with a history of chronic viral infections (e.g., HIV, hepatitis B, hepatitis C) or with a history of a malignancy (except non-melanoma skin cancer). - Due to interference with sirolimus metabolism, subjects will not be allowed to receive concomitant rifampin, ketoconazole,voriconazole, itraconazole, erythromycin, or clarithromycin during the study. - Patients with any type of interstitial lung disease. For Healthy control Subjects: - Subjects who are pregnant. - Subjects with any acute or chronic illness. |
Country | Name | City | State |
---|---|---|---|
United States | SUNY Upstate Medical University | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York - Upstate Medical University | Pfizer |
United States,
Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medi — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of the disease activity | 1 year | ||
Secondary | decrease of the amount of prednisone needed to treat SLE. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04461158 -
CCCR Lupus Patient Navigator Program
|
N/A | |
Completed |
NCT02006784 -
Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT01072734 -
Auto-immunity in Lupus Patients After Influenza Vaccine
|
Phase 2 | |
Completed |
NCT03626311 -
Omega-3 Replacement With Krill Oil in Disease Management of SLE
|
N/A | |
Withdrawn |
NCT02779153 -
Acthar SLE (Systemic Lupus Erythematosus)
|
Phase 4 | |
Completed |
NCT01992666 -
GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus
|
N/A | |
Recruiting |
NCT00582881 -
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
|
||
Terminated |
NCT02811094 -
LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse
|
N/A | |
Recruiting |
NCT05458622 -
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
|
Phase 3 | |
Recruiting |
NCT06144710 -
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
|
Phase 1 | |
Completed |
NCT03031925 -
Detection of Annexin A2 in Systemic Lupus Erythematosus
|
N/A | |
Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
Recruiting |
NCT02782039 -
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
|
||
Recruiting |
NCT05567198 -
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
|
||
Recruiting |
NCT05747651 -
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
|
||
Recruiting |
NCT03030976 -
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Recruiting |
NCT06249438 -
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
|
Phase 1 | |
Not yet recruiting |
NCT05724940 -
Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
|
||
Recruiting |
NCT06032923 -
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
|
Phase 1/Phase 2 | |
Completed |
NCT03122431 -
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
|
Phase 4 |